Starpharma secures majority ownership of Petalion

Summary by 6ix AI

Starpharma Holdings Limited has announced that it has secured majority ownership of Petalion Therapeutics, increasing its equity interest from a minority stake to a controlling share. This acquisition allows Starpharma to lead the development of a targeted oncology program utilizing its DEP® platform, aligning development priorities with its broader strategy. Starpharma will contribute funds and resources to advance the program, while Medicxi will maintain a significant stake and strategic role in the partnership. The transaction is expected to enhance Starpharma's oncology portfolio and facilitate the selection of a lead candidate for further development.

Written by 6ix AI from the company’s filing. How 6ix writes summaries